The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Amgen; AstraZeneca/MedImmune; Janssen; Takeda
Consulting or Advisory Role - AstraZeneca Spain; Janssen Oncology; Lilly; Takeda
Research Funding - AstraZeneca Spain (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Pfizer; Roche/Genentech; Takeda
Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in non-small-cell lung cancer (NSCLC) with c-METexon 14 skipping mutations (METex14).
 
Mariana da Rocha Almeida Brandao
Consulting or Advisory Role - Amgen; AstraZeneca; Daiichi Sankyo; Janssen; Pierre Fabre; Sanofi
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Janssen; MSD; Pfizer; Takeda
Research Funding - AstraZeneca; Boehringer Ingelheim; Merck; Merus NV; Roche/Genentech; Sanofi
Travel, Accommodations, Expenses - AstraZeneca; Sanofi; Takeda
 
Jon Zugazagoitia
Honoraria - AstraZeneca Spain; Bristol-Myers Squibb/Celgene; Guardant Health; NanoString Technologies; Pfizer; Roche/Genentech; Sanofi/Regeneron
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb/Celgene; Guardant Health; Novartis; Novartis; Pfizer; Sanofi/Regeneron
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb/Celgene; Guardant Health; MSD Oncology; NanoString Technologies; Pfizer; Roche; Takeda
Research Funding - AstraZeneca (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb/Celgene; Roche/Genentech; Sanofi
 
Anne-Marie C. Dingemans
Consulting or Advisory Role - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Daiichi Sankyo/Lilly (Inst); Janssen Oncology (Inst); Mirati Therapeutics (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Speakers' Bureau - Amgen (Inst); Janssen (Inst); Lilly (Inst)
(OPTIONAL) Uncompensated Relationships - European Organisation for Research and Treatment of Cancer (EORTC)
 
Michaël Duruisseaux
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen Oncology; MSD; Pfizer; Roche; Takeda
Travel, Accommodations, Expenses - Boehringer Ingelheim; MSD
 
Pauline Parent
Travel, Accommodations, Expenses - Roche
 
Oscar Juan-Vidal
No Relationships to Disclose
 
Alexander I. Spira
Leadership - Next Oncology (Inst)
Stock and Other Ownership Interests - Lilly
Honoraria - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Takeda
Consulting or Advisory Role - Amgen; Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Sanofi; Sanofi; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); Arch Therapeutics (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); Mirati Therapeutics (Inst); nalo therapeutics (Inst); Novartis (Inst); Plexxikon (Inst); Regeneron; Revolution Medicines (Inst); Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Scorpion Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst)
 
Cecile Vicier
Honoraria - seagen
Consulting or Advisory Role - BMSi; Daiichi Sankyo/Astra Zeneca; Novartis (Inst); Owkin; Pfizer
Research Funding - BMS Norway (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Novartis; Pfizer
 
Gerard Zalcman
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Da Volterra; Inventiva Pharma; Lilly; MSD Oncology; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Da Volterra (Inst); Inventiva Pharma (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche (Inst)
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb; Pfizer (Inst); Roche (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Bristol-Myers Squibb; Lilly; Pfizer; Roche
 
Ben Barasa
Employment - Merus
 
Chris Yan
Employment - Merus
 
Petra Doze
Employment - Merus
 
Andrew K. Joe
Employment - Merus
Leadership - Merus
Stock and Other Ownership Interests - Merck Sharp & Dohme; Merus; Sanofi
 
Gianluca Laus
Employment - Merus
Stock and Other Ownership Interests - AstraZeneca; Merus
 
Enriqueta Felip
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; BeiGene; Boehringer Ingelheim; Bristol Myers Squibb; Daiichi Sankyo; Gilead Sciences; GlaxoSmithKline; Janssen; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Peptomyc; Pfizer; Regeneron; Roche; Sanofi; Takeda; Turning Point Therapeutics
Speakers' Bureau - Amgen; AstraZeneca; Bristol Myers Squibb; Daiichi Sankyo; Genentech; Janssen; Lilly; Medical Trends; Medscape; Merck Serono; Merck Sharp & Dohme; Peervoice; Pfizer; Roche; Sanofi; Takeda; Touch Oncology
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Roche
Other Relationship - GRIFOLS
(OPTIONAL) Uncompensated Relationships - "ETOP IBCSG Partners" Member of the Scientific Committee; Member of the Scientific Advisory Committee -Hospital Universitari Parc Taulí-; SEOM (Sociedad Española de Oncología Médica), President from 2021-2023